Fusion Antibodies P/S 2024

Fusion Antibodies Aktienanalyse

What does Fusion Antibodies do?

The company Fusion Antibodies PLC is a biotechnology company specializing in the production of antibodies for medical and scientific research. The company, based in Belfast, Northern Ireland, was founded in 2001 and has been listed on the London Stock Exchange since 2017. Fusion Antibodies' business model is based on the development of customized antibodies for customers in the pharmaceutical, biotech, diagnostics, and academic research sectors. The company offers a wide range of services throughout the entire antibody development process, from antigen design to the production of recombinant antibodies and antibody conjugates. Fusion Antibodies divides its business operations into three main departments: antibody engineering, antibody production, and antibody conjugation. The antibody engineering department is involved in the discovery and optimization of antibodies using advanced technologies such as phage display and hybridoma technologies. In the antibody production department, the desired antibodies are produced through cell culture or recombinant technologies. Finally, in the antibody conjugation department, the antibody is coupled with other molecules such as enzymes, toxins, or fluorescent dyes to generate new therapeutic agents or diagnostic systems. Fusion Antibodies also offers a variety of products that can be either individually configured by customers or purchased as standard products. The portfolio of standard products includes antibodies against known target molecules such as GFP, His-tag, and HA-tag, as well as antibodies tailored to specific applications such as anti-idiotypic antibodies or antibodies for the detection of posttranslational modifications of proteins. In addition, Fusion Antibodies also offers a customized service for the production of antibodies against customer-specific target molecules, tailored to the individual needs of the customer. Fusion Antibodies has numerous customers from the biopharmaceutical and biotechnology industry, as well as from academic research. The company works closely with its customers to meet their specific requirements and offers flexibility and a creative approach through its technology platform in developing solutions for their challenges. The company has a strong R&D department and continuously invests in the development of new technologies and products to maintain and expand its competitiveness. Fusion Antibodies also has partnerships with other companies and institutions in the biotech industry to jointly develop new technologies and products. Overall, Fusion Antibodies is an innovative company specializing in the development of antibodies for use in medical and scientific research. Through its wide range of services, products, and partnerships, the company has solidified its position in the biotech industry and is expected to continue to play an important role in the development of new therapeutic and diagnostic approaches. Fusion Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Fusion Antibodies's P/S Ratio

Fusion Antibodies's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Fusion Antibodies's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Fusion Antibodies's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Fusion Antibodies’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Fusion Antibodies stock

What is the price-to-earnings ratio of Fusion Antibodies?

The price-earnings ratio of Fusion Antibodies is currently 0.78.

How has the price-earnings ratio of Fusion Antibodies changed compared to last year?

The price-to-earnings ratio of Fusion Antibodies has increased by 41.82% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Fusion Antibodies high compared to other companies?

Yes, the price-to-earnings ratio of Fusion Antibodies is high compared to other companies.

How does an increase in the price-earnings ratio of Fusion Antibodies affect the company?

An increase in the price-earnings ratio of Fusion Antibodies would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Fusion Antibodies affect the company?

A decrease in the price-earnings ratio of Fusion Antibodies would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Fusion Antibodies?

Some factors that influence the price-earnings ratio of Fusion Antibodies are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Fusion Antibodies pay?

Over the past 12 months, Fusion Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Antibodies is expected to pay a dividend of 0 GBP.

What is the dividend yield of Fusion Antibodies?

The current dividend yield of Fusion Antibodies is .

When does Fusion Antibodies pay dividends?

Fusion Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Antibodies?

Fusion Antibodies paid dividends every year for the past 0 years.

What is the dividend of Fusion Antibodies?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Antibodies located?

Fusion Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Antibodies from 9/9/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Fusion Antibodies pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Fusion Antibodies in the year 2023?

In the year 2023, Fusion Antibodies distributed 0 GBP as dividends.

In which currency does Fusion Antibodies pay out the dividend?

The dividends of Fusion Antibodies are distributed in GBP.